NKGen Biotech, Inc. 8-K

What Happened

• NKGen Biotech, Inc. and subsidiary NKGen Operating Biotech, Inc. entered into a third amendment to their secured promissory note with AlpineBrook Capital GP I Limited on January 30, 2026. The amendment (the Alpine Third Amendment) provides an additional $251,000 of funding and increases the principal balance of the Note to $26,758,106. The amendment clarifies that interest on this additional loan accrues from January 30, 2026.

Key Details

• Lenders/parties: AlpineBrook Capital GP I Limited and the Borrowers (NKGen Biotech, Inc. and NKGen Operating Biotech, Inc.).
• Date of amendment: January 30, 2026 (Note originally dated January 5, 2026; prior amendments on January 12, 2026 and a second amendment).
• Incremental funding: $251,000 (designated the "Fourth Additional New Loan").
• New principal balance of the Note: $26,758,106; interest on the new funds accrues from Jan 30, 2026.

Why It Matters

• This filing documents a material change in the company’s financing: NKGen has increased its debt under an existing secured note, which affects its outstanding obligations and future interest costs. For investors, this is a clear financing event showing continued support from AlpineBrook but also slightly higher leverage and accruing interest expense. The full amendment is filed as an exhibit to the 8-K for anyone who wants the definitive terms.